Established in 2009, Chengdu Uni-Asia Hospital is located in Chengdu, Sichuan Province, western China. It is a modern, international oncology specialty hospital focusing on advanced technologies for minimally invasive and precise cancer treatment. The hospital is among the top-ranking institutions in China in terms of the volume of minimally invasive cancer surgeries performed.

Chengdu Uni-Asia Hospital operates two campuses in China: Chengdu Campus & Zigong Campus. With a combined area of 36,000 square meters, the hospital employs more than 600 staff, including over 100 doctors, and offers more than 500 inpatient beds. Each year, the hospital admits over 6,000 inpatients from China and abroad, and treats more than 10,000 cancer patients, approximately two-thirds of whom come from outside Chengdu.

In 2024, the hospital treated 8,000 cancer patients, including 3,000 new cases. Many of them are Chinese political figures and business elites.

The hospital offers a comprehensive range of cancer treatments, including Superfine Vascular Interventional Therapy, NanoKnife Ablation Therapy, Cryoablation Immune Therapy, Iodine Seed Brachytherapy, Integrated Chinese-Western Medicine Therapy, Intensity-Modulated Radiation Therapy (IMRT), Targeted Therapy, Immunotherapy and Combined Multimodal Treatments. An interdisciplinary team of specialists collaborates closely to develop personalized and comprehensive treatment plans for every patient.